Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab plus CyBorD versus CyBorD in newly diagnosed systemic AL amyloidosis
2016-001737-27Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of daratumumab in light-chain amyloidosis (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall complete hematologic response rate. Started Nov 2017; status: active.
02
Drugs
daratumumab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2016-001737-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001737-27.